Spots Global Cancer Trial Database for axitinib
Every month we try and update this database with for axitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | NCT02579811 | Metastatic Rena... | Axitinib | 18 Years - | Case Comprehensive Cancer Center | |
| Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor | NCT00454649 | Neoplasms | Axitinib + Pacl... Axitinib + Pacl... Axitinib + Pacl... Axitinib + Pacl... Axitinib + Doce... Axitinib + Doce... Axitinib + Cape... Axitinib + Cape... Axitinib + Gemc... Axitinib + Peme... | 18 Years - | Pfizer | |
| Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | NCT02489695 | Papillary Renal... | Axitinib | 18 Years - | Centre Leon Berard | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer | NCT01486251 | Colorectal Carc... | axitinib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma | NCT02859012 | Recurrent ACC, ... | Axitinib Observation | - | Seoul National University Hospital | |
| An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | NCT04941768 | Carcinoma, Rena... | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | ||
| Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | NCT02579811 | Metastatic Rena... | Axitinib | 18 Years - | Case Comprehensive Cancer Center | |
| Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | NCT01409200 | Metastatic Mali... Prostate Ductal... Stage III Prost... Stage IV Prosta... | Antiandrogen Th... Axitinib Radical Prostat... Regional Lymph ... | 18 Years - | M.D. Anderson Cancer Center | |
| Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer | NCT00735904 | Carcinoma, Non-... | AG-013736 gemcitabine cisplatin | 18 Years - | Pfizer | |
| Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations | NCT05904730 | Breast Cancer Ovarian Cancer Breast Neoplasm... Ovarian Neoplas... BRCA Mutation HER2-positive B... HER2-negative B... HER-2 Protein O... | Axitinib | 18 Years - | Lynkcell Europe | |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | NCT01744249 | Neuroendocrine ... Advanced Cancer | Axitinib Sandostatin LAR Placebo | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | NCT03592199 | Clear Cell Rena... | Sunitinib | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma | NCT01562197 | Glioblastoma Mu... | axitinib Axitinib plus L... | 18 Years - 99 Years | Universitair Ziekenhuis Brussel | |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | NCT01744249 | Neuroendocrine ... Advanced Cancer | Axitinib Sandostatin LAR Placebo | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | NCT02489695 | Papillary Renal... | Axitinib | 18 Years - | Centre Leon Berard | |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | NCT03592199 | Clear Cell Rena... | Sunitinib | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Axitinib as Maintenance Treatment in Patients With Metastatic CRC | NCT01483638 | Colorectal Carc... | axitinib placebo | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | NCT02129647 | Neurofibromatos... Vestibular Schw... | Axitinib | 18 Years - | NYU Langone Health | |
| Axitinib as Maintenance Treatment in Patients With Metastatic CRC | NCT01483638 | Colorectal Carc... | axitinib placebo | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | NCT01174238 | Melanoma | Axitinib Carboplatin Paclitaxel | 18 Years - | University of California, San Francisco | |
| Axitinib + Ipilimumab in Advanced Melanoma | NCT04996823 | Melanoma | Ipilimumab Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy | NCT03826589 | Cervical Cancer | Avelumab Axitinib | 18 Years - | The University of Hong Kong | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) | NCT05012865 | Renal Cell Carc... | avelumab axitinib | 20 Years - | Pfizer | |
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma | NCT01649180 | Renal Cell Carc... | Axitinib | 18 Years - | PrECOG, LLC. | |
| A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus | NCT01798446 | Renal Cell Carc... Nonclear Cell Temsirolimus Re... | Axitinib | 18 Years - | Seoul National University Hospital | |
| Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer | NCT00735904 | Carcinoma, Non-... | AG-013736 gemcitabine cisplatin | 18 Years - | Pfizer | |
| Expansion Trial for Axitinib In Head And Neck Cancer | NCT02762513 | Squamous Cell C... | Axitinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | NCT04540705 | Renal Cell Carc... | Nivolumab Axitinib Cabozantinib | 18 Years - | Bristol-Myers Squibb | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | NCT04337970 | Kidney Cancer Renal Cell Carc... Unresectable Re... Metastatic Rena... | Talazoparib Axitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | NCT02156895 | Advanced Renal ... | Axitinib | 18 Years - | Pfizer | |
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | NCT01441388 | Carcinoma, Rena... Glioblastoma Carcinoma, Hepa... | Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... | 18 Years - | Pfizer | |
| Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | NCT05263609 | Renal Cell Canc... | Axitinib Pembrolizumab | 18 Years - 99 Years | University of Oklahoma | |
| Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | NCT02782403 | Accelerated Pha... Blast Phase Chr... Chronic Phase P... Philadelphia Ch... | Axitinib Bosutinib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer | NCT04958473 | Renal Cell Carc... Clear Cell Rena... | Sintilimab Axitinib | 18 Years - | Tianjin Medical University Second Hospital | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| Strata PATH™ (Precision Indications for Approved Therapies) | NCT05097599 | Cancer Advanced Solid ... | lorlatinib encorafenib + b... talazoparib sacituzumab gov... axitinib | 18 Years - | Strata Oncology | |
| Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) | NCT01263769 | Kidney Cancer | Axitinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | NCT05808608 | Renal Cell Carc... First-line Trea... Non Clear Cell ... Sarcomatoid Ren... | AK104 Axitinib | 18 Years - 75 Years | West China Hospital | |
| Axitinib + Ipilimumab in Advanced Melanoma | NCT04996823 | Melanoma | Ipilimumab Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor | NCT00454649 | Neoplasms | Axitinib + Pacl... Axitinib + Pacl... Axitinib + Pacl... Axitinib + Pacl... Axitinib + Doce... Axitinib + Doce... Axitinib + Cape... Axitinib + Cape... Axitinib + Gemc... Axitinib + Peme... | 18 Years - | Pfizer | |
| Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | NCT02636725 | Alveolar Soft P... Soft Tissue Sar... | Axitinib Pembrolizumab | 16 Years - | University of Miami | |
| A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy | NCT01693822 | Clear-cell Meta... | Axitinib | 18 Years - | Institute of Cancer Research, United Kingdom | |
| A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | NCT01174238 | Melanoma | Axitinib Carboplatin Paclitaxel | 18 Years - | University of California, San Francisco | |
| Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer | NCT00094094 | Lung Neoplasms Carcinoma, Non-... | axitinib | 18 Years - | Pfizer | |
| A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | NCT03289533 | Carcinoma, Hepa... | Avelumab (MSB00... Axitinib (AG-01... | 20 Years - | Pfizer | |
| A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | NCT03289533 | Carcinoma, Hepa... | Avelumab (MSB00... Axitinib (AG-01... | 20 Years - | Pfizer | |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | NCT05949632 | Advanced Solid ... | INCB099280 axitinib | 18 Years - | Incyte Corporation | |
| Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma | NCT06279403 | Clear-cell Meta... Immune Checkpoi... Cytoreductive N... | Toripalimab Cytoreductive N... Axitinib | 18 Years - 80 Years | RenJi Hospital | |
| Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | NCT04493203 | Advanced Melano... Unresectable Me... | Nivolumab Axitinib | 18 Years - | University of Pittsburgh | |
| SLM + Axitinib for Clear Cell RCC | NCT02535533 | Advanced Metast... | Selenomethionin... Axitinib Selenomethionin... Axitinib Selenomethionin... | 18 Years - | University of Iowa | |
| Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | NCT00835978 | Carcinoma, Rena... | axitinib axitinib axitinib | 18 Years - | Pfizer | |
| Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | NCT04033991 | Carcinoma Renal Cell | Sunitinib Axitinib | 18 Years - | Pfizer | |
| Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis | NCT05070221 | Melanoma Stage ... | Recombinant Onc... Recombinant hum... Axitinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | NCT04693468 | Advanced Malign... Metastatic Mali... Recurrent Malig... | Axitinib Crizotinib Palbociclib Ise... Talazoparib Tos... | 18 Years - | M.D. Anderson Cancer Center | |
| Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib | NCT01352728 | Hepatocellular ... | Axitinib | 18 Years - | Chinese University of Hong Kong | |
| Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor | NCT02261207 | Solitary Fibrou... | Axitinib | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | NCT04941768 | Carcinoma, Rena... | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | ||
| A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | NCT04540705 | Renal Cell Carc... | Nivolumab Axitinib Cabozantinib | 18 Years - | Bristol-Myers Squibb | |
| Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN) | NCT02597322 | cT2a N0NxM0 Ren... | AXITINIB | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib | NCT01540526 | Solid Malignanc... Metastatic Cast... | axitinib | 18 Years - | University of Wisconsin, Madison | |
| Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy | NCT03826589 | Cervical Cancer | Avelumab Axitinib | 18 Years - | The University of Hong Kong | |
| Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | NCT01508117 | Glioblastoma Mu... | Axitinib Radiation Thera... | 70 Years - | University of Cincinnati | |
| Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients | NCT01599754 | Clear Cell Rena... | Axitinib Placebo | 18 Years - | SFJ Pharmaceuticals, Inc. | |
| A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | NCT01999972 | Advanced Solid ... | axitinib crizotinib axitinib crizotinib axitinib crizotinib | 18 Years - | Pfizer | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | NCT04337970 | Kidney Cancer Renal Cell Carc... Unresectable Re... Metastatic Rena... | Talazoparib Axitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | NCT02814461 | Advanced Hepato... | Axitinib Radiation | 20 Years - 85 Years | Shin Kong Wu Ho-Su Memorial Hospital | |
| Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | NCT02156895 | Advanced Renal ... | Axitinib | 18 Years - | Pfizer | |
| Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | NCT05650164 | Renal Cell Carc... | avelumab axitinib | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer | NCT00842244 | Stomach Neoplas... Advanced Gastri... | axitinib capecitabine cisplatin | 18 Years - | Pfizer | |
| A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | NCT01999972 | Advanced Solid ... | axitinib crizotinib axitinib crizotinib axitinib crizotinib | 18 Years - | Pfizer | |
| Survival Prolongation by Rationale Innovative Genomics | NCT03386929 | Non-small Cell ... Non-small Cell ... | Avelumab Axitinib Palbociclib | 18 Years - | Worldwide Innovative Network Association | |
| Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | NCT03092856 | Clear Cell Rena... Metastatic Rena... Recurrent Renal... Stage IV Renal ... | Anti-OX40 Antib... Axitinib Laboratory Biom... Placebo | 18 Years - | University of Southern California | |
| Expansion Trial for Axitinib In Head And Neck Cancer | NCT02762513 | Squamous Cell C... | Axitinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma | NCT05256472 | Renal Cell Carc... First-line Trea... | AK104 axitinib | 18 Years - 75 Years | Akeso | |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | NCT05805501 | Renal Cell Carc... | Tobemstomig Tiragolumab Pembrolizumab Axitinib | 18 Years - | Hoffmann-La Roche | |
| Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors | NCT05768464 | Non-clear Renal... | Toripalimab Axitinib | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| CARE1 Pragmatic Clinical Trial | NCT06364631 | Metastatic Kidn... Metastatic Kidn... | Nivolumab Ipilimumab Pembrolizumab Cabozantinib Axitinib Lenvatinib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
